KeyCorp Initiates Coverage on Lumexa Imaging (NASDAQ:LMRI)

Research analysts at KeyCorp began coverage on shares of Lumexa Imaging (NASDAQ:LMRI) in a note issued to investors on Thursday, Marketbeat reports. The firm set an “overweight” rating on the stock.

A number of other analysts have also commented on LMRI. Barclays lifted their target price on shares of Lumexa Imaging from $9.00 to $13.00 and gave the stock an “overweight” rating in a report on Friday, August 28th. Wall Street Zen lowered Lumexa Imaging from a “buy” rating to a “hold” rating in a research report on Saturday, September 12th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Lumexa Imaging in a research note on Tuesday. Finally, Deutsche Bank Aktiengesellschaft set a $16.00 price objective on Lumexa Imaging in a report on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $17.50.

Lumexa Imaging Trading Up 3.3%

Lumexa Imaging stock traded up $0.33 during trading hours on Thursday, reaching $10.21. 441,200 shares of the company’s stock traded hands, compared to its average volume of 362,982. The company has a debt-to-equity ratio of 1.40, a quick ratio of 1.44 and a current ratio of 1.44. Lumexa Imaging has a fifty-two week low of $6.45 and a fifty-two week high of $19.45. The firm’s 50 day moving average is $11.37 and its 200-day moving average is $10.42.

Lumexa Imaging (NASDAQ:LMRI) last posted its quarterly earnings results on Wednesday, August 12th. The company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.17. The business had revenue of $264.16 million for the quarter. Lumexa Imaging has set its FY 2026 guidance at 0.710-0.770 EPS. As a group, research analysts forecast that Lumexa Imaging will post 0.25 earnings per share for the current year.

Institutional Trading of Lumexa Imaging

Hedge funds have recently added to or reduced their stakes in the business. Squarepoint Ops LLC grew its stake in Lumexa Imaging by 506.9% in the second quarter. Squarepoint Ops LLC now owns 79,934 shares of the company’s stock valued at $902,000 after acquiring an additional 66,763 shares during the period. Readystate Asset Management LP raised its position in shares of Lumexa Imaging by 11.5% during the second quarter. Readystate Asset Management LP now owns 250,533 shares of the company’s stock worth $2,826,000 after purchasing an additional 25,778 shares during the period. AXQ Capital LP bought a new position in shares of Lumexa Imaging during the 2nd quarter valued at about $128,000. Bank of America Corp DE acquired a new position in shares of Lumexa Imaging in the 2nd quarter valued at approximately $200,000. Finally, Jupiter Topco LLC bought a new stake in Lumexa Imaging during the 2nd quarter worth approximately $24,269,000.

About Lumexa Imaging

Lumexa Imaging, Inc (NASDAQ: LMRI) is an outpatient diagnostic imaging company that provides medical imaging services to patients and referring healthcare providers in the United States. Its services are designed to support the diagnosis, monitoring and management of a wide range of medical conditions.

The company’s imaging capabilities include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET/CT), ultrasound, mammography and X-ray services. Lumexa also provides related radiology and imaging-support services through its outpatient centers and other care-delivery arrangements.

Lumexa Imaging was formerly known as Akumin Inc and adopted the Lumexa Imaging name as part of its corporate rebranding.